Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK.

Diabet Med. 2011 Oct;28(10):1176-81. doi: 10.1111/j.1464-5491.2011.03331.x.

PMID:
21923696
2.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Zerilli T, Pyon EY.

Clin Ther. 2007 Dec;29(12):2614-34. doi: 10.1016/j.clinthera.2007.12.034. Review.

PMID:
18201579
3.

Sitagliptin: a novel drug for the treatment of type 2 diabetes.

Choy M, Lam S.

Cardiol Rev. 2007 Sep-Oct;15(5):264-71. Review.

PMID:
17700385
4.

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

Scheen AJ.

Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1265-76. doi: 10.1517/17425255.2010.513699. Review.

PMID:
20707611
5.

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

Bailey CJ, Green BD, Flatt PR.

Expert Opin Investig Drugs. 2010 Aug;19(8):1017-25. doi: 10.1517/13543784.2010.505235. Review.

PMID:
20629618
6.

Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP.

Curr Med Res Opin. 2008 Feb;24(2):489-96. doi: 10.1185/030079908X261069 . Review.

PMID:
18182122
7.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
8.

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

Chwieduk CM.

Drugs. 2011 Feb 12;71(3):349-61. doi: 10.2165/11206060-000000000-00000. Review.

PMID:
21319871
9.

Sitagliptin.

Lyseng-Williamson KA.

Drugs. 2007;67(4):587-97. Review.

PMID:
17352516
10.

Sitagliptin and metformin--novel combination therapy.

Seyoum B.

Expert Opin Pharmacother. 2011 Mar;12(4):641-6. doi: 10.1517/14656566.2011.556113. Epub 2011 Feb 4. Review.

PMID:
21291346
11.

[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].

Abel T, Fehér J.

Orv Hetil. 2010 Jun 20;151(25):1012-6. doi: 10.1556/OH.2010.28910. Review. Hungarian.

PMID:
20519186
12.

Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

Gallwitz B.

Drugs Today (Barc). 2007 Nov;43(11):801-14. doi: 10.1358/dot.2007.43.11.1157620. Review.

PMID:
18174966
13.

Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.

Furukawa S, Kumagi T, Miyake T, Ueda T, Niiya T, Nishino K, Murakami S, Murakami M, Matsuura B, Onji M.

Endocr J. 2012;59(4):329-33. Epub 2012 Jan 21. Review.

14.

Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.

Dhillon S.

Drugs. 2010 Mar 5;70(4):489-512. doi: 10.2165/11203790-000000000-00000. Review.

PMID:
20205490
15.

Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.

Pham DQ, Nogid A, Plakogiannis R.

Am J Health Syst Pharm. 2008 Mar 15;65(6):521-31. doi: 10.2146/ajhp070248. Review.

PMID:
18319497
16.

Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.

Doggrell SA.

Expert Opin Pharmacother. 2011 Sep;12(13):2055-67. doi: 10.1517/14656566.2011.576671. Epub 2011 May 3. Review.

PMID:
21534885
17.

Potential role of non-insulin adjunct therapy in Type 1 diabetes.

George P, McCrimmon RJ.

Diabet Med. 2013 Feb;30(2):179-88. doi: 10.1111/j.1464-5491.2012.03744.x. Review.

PMID:
22804102
18.

A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.

Eligar VS, Bain SC.

Drug Des Devel Ther. 2013 Aug 30;7:893-903. doi: 10.2147/DDDT.S32331. eCollection 2013. Review.

19.

Using prandial insulin to achieve glycemic control in type 2 diabetes.

Dailey GE.

J Fam Pract. 2007 Sep;56(9):735-42. Review. No abstract available.

PMID:
17764645
20.

The glucose triad and its role in comprehensive glycaemic control: current status, future management.

Ceriello A.

Int J Clin Pract. 2010 Nov;64(12):1705-11. doi: 10.1111/j.1742-1241.2010.02517.x. Epub 2010 Sep 23. Review.

Supplemental Content

Support Center